Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Pharmstandard

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 13
Average round size
info
The average size of a deal this fund participated in
$23M
Portfolio companies 11
Rounds per year 0.72
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.15
Exits 6
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

The main office of represented Corporate Investor is situated in the Moscow. The fund was located in Europe if to be more exact in Russian Federation.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Pharmstandard, startups are often financed by Torrey Pines Investment, Intersouth Partners, TVM Capital. The meaningful sponsors for the fund in investment in the same round are Inbio Ventures, Virginia Tech Carilion (VTC) Innovation Fund, Intersouth Partners. In the next rounds fund is usually obtained by Inbio Ventures, yet2Ventures, Wellington Management.

Comparing to the other companies, this Pharmstandard performs on 26 percentage points more the average number of lead investments. The real fund results show that this Corporate Investor is 35 percentage points more often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2017.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Real Time, Medical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight enGene, Viriom, Avelas Biosciences.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pharmstandard:
Typical Co-investors
Pharmstandard is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pharmstandard:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Amity Supply New York, New York, United States
Angels with Attitude Seattle, United States, Washington
Black Dog Venture Partners Arizona, Tempe, United States
Ginkgo Bioworks Boston, Massachusetts, United States
Growceanu Angel Investment -
Hinokiya Group Chiyoda, Japan
ICONIZ California, Los Angeles, United States
KD Partners -
Kerlink Bretagne, France, Rennes
N+1 Capital Delhi, Delhi, India
Nanchang Xinshiji Chuangtou China, Guangdong, Jiangxi
Neogen.biz -
Next Blockchain Capital -
Oakhouse Partners California, San Francisco, United States
Tianjin Yahui Mingze Asset Management China, Guangdong, Tianjin
Tide Capital -
University of New Brunswick Canada, Fredericton, New Brunswick
YMCI Group China, Kunming, Yunnan
Zhongping Capital China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Eyewear
Medical
Pharmaceutical
$6M21 Mar 2019 Virginia, United States

Eyewear
Medical
Pharmaceutical
$8M07 Dec 2017 Virginia, United States

Biotechnology
Health Care
Pharmaceutical
$12M06 Dec 2017 San Diego, California, United States

Genotek

Bioinformatics
Clinical Trials
Genetics
Health Care
$1M17 Feb 2017 Moscow, Moscow, Russia

Avelas Biosciences

Biotechnology
Diagnostic Equipment
Life Science
Real Time
Surgical Devices
$20M18 Aug 2016 San Diego, California, United States

TransMedics

Health Care
Medical
Medical Device
$12M12 Jul 2016 Massachusetts, United States

Biotechnology
Health Care
Therapeutics
$60M15 Mar 2016 Durham, North Carolina, United States

Jounce Therapeutics

Biotechnology
Drug Discovery
Pharmaceutical
Therapeutics
$56M23 Apr 2015 Cambridge, Massachusetts, United States

enGene

Biotechnology
Diabetes
Genetics
Health Care
$11M26 Jan 2015 Vancouver, British Columbia, Canada

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pharmstandard?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 13
Average round size 23M
Rounds per year 0.72
Peak activity year 2016
Lead investments 3
Follow on index 0.15
Exits 6
Group Appearance index 0.77

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Eyewear
Medical
Pharmaceutical
$6M21 Mar 2019 Virginia, United States

Eyewear
Medical
Pharmaceutical
$8M07 Dec 2017 Virginia, United States

Biotechnology
Health Care
Pharmaceutical
$12M06 Dec 2017 San Diego, California, United States

Genotek

Bioinformatics
Clinical Trials
Genetics
Health Care
$1M17 Feb 2017 Moscow, Moscow, Russia

Avelas Biosciences

Biotechnology
Diagnostic Equipment
Life Science
Real Time
Surgical Devices
$20M18 Aug 2016 San Diego, California, United States

TransMedics

Health Care
Medical
Medical Device
$12M12 Jul 2016 Massachusetts, United States

Biotechnology
Health Care
Therapeutics
$60M15 Mar 2016 Durham, North Carolina, United States

Jounce Therapeutics

Biotechnology
Drug Discovery
Pharmaceutical
Therapeutics
$56M23 Apr 2015 Cambridge, Massachusetts, United States

enGene

Biotechnology
Diabetes
Genetics
Health Care
$11M26 Jan 2015 Vancouver, British Columbia, Canada

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: